Skip to main content
Top
Published in: Breast Cancer 1/2019

01-01-2019 | Correction

Correction to: Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients

Authors: K. Okumatsu, T. Tsujimoto, K. Wakaba, A. Seki, R. Kotake, T. Yamauchi, S. Hirayama, H. Kobayashi, H. Yamauchi, K. Tanaka

Published in: Breast Cancer | Issue 1/2019

Login to get access

Excerpt

In the original publication of this article, Table 1 was published incorrectly. The correct Table 1 is given in the following page.
Table 1
Baseline characteristics of study participants
Characteristics
Intervention group (n = 21)
Usual-care group (n = 11)
P
Age, years (mean ± SD)
51 ± 6
53 ± 5
0.14
Race, no. (%)
     
 Asian (Japanese)
21 (100)
11 (100)
 
Education, no. (%)
   
0.04
 High school
6 (29)
0
 
 Some college
12 (57)
5 (45)
 
 ≧ College
3 (14)
6 (55)
 
Time since cancer diagnosis, years (mean ± SD)
4 ± 2
3 ± 1
0.14
Disease stage, no. (%)
   
0.71
 0
1 (5)
0 (0)
 
 I
10 (48)
8 (73)
 
 II
7 (33)
2 (18)
 
 III
3 (14)
1 (9)
 
Postmenopausal at baseline, (%)
7 (33)
4 (11)
0.62
Cancer treatment, no. (%)
     
 Surgery
21 (100)
11 (100)
 Chemotherapy
8 (38)
3 (27)
0.31
 Radiation
13 (62)
8 (73)
0.66
 Tamoxifen
14 (67)
7 (64)
0.14
 Aromatase inhibitor
7 (33)
4 (36)
Smoking habit, no. (%)
   
0.68
 Never
16 (76)
8 (73)
 
 Former
4 (19)
3 (27)
 
 Current
1 (5)
0 (0)
 
SD standard deviation
Metadata
Title
Correction to: Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients
Authors
K. Okumatsu
T. Tsujimoto
K. Wakaba
A. Seki
R. Kotake
T. Yamauchi
S. Hirayama
H. Kobayashi
H. Yamauchi
K. Tanaka
Publication date
01-01-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 1/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0902-4

Other articles of this Issue 1/2019

Breast Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine